PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...

No new safety issues related to PGN-EDO51 have been observed since the Company’s last safety update as of January 23, 2025. “With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data ...

ILOILO CITY — The construction of the 32.47-kilometer Panay-Guimaras-Negros (PGN) island bridges project is scheduled to start in July 2026, Iloilo City Mayor Jerry Treñas announced on Monday. Treñas, ...

S hares of PepGen (NASDAQ:PEPG) were down 22% midday Monday following news the FDA has placed a clinical hold on its Investigational New Drug application to initiate a Phase 2 study for its drug ...

Recent Program Updates PGN-EDODM1: Myotonic Dystrophy Type 1 (DM1) PGN-EDO51: Duchenne Muscular Dystrophy (DMD) The 10 mg/kg cohort is fully enrolled (n=4) and participants in the 5 mg/kg cohort ...

Oral Presentations PGN-EDODM1, PepGen's investigational candidate in development for the treatment of DM1, utilizes the Company's proprietary EDO technology to deliver a therapeutic ...

BOSTON, February 24, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of ...

"Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dose of PGN-EDODM1. We believe these data contribute to the ...